Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References Expected currency impact for full year 2022 and 2023 Currency impact vs. PY %pts, assuming late October exchange rates prevail in 2022 and 2023 FX impact on Net sales 2 I I I 2 I FX impact on Core operating income I I I I -4 -4 -5 -6 -8 -7 -6 -7 I -9 -9 -8 I I I -11 I I I FY Q1 Q2 Q3 Q4 FY FY FY Q1 Q2 Q3 Q4 FY ¦ FY I I I I I I I I I I 2021 2022 2023 2021 2022 2023 Actual Simulation 26 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation